Please assess the completion status of the following clinical trial:

Trial Title: Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed acute lymphoblastic leukemia (ALL)~  * More than 25% lymphoblasts in bone marrow~    * Patients with myeloid antigen expression AND unequivocal lymphoid immunophenotype are eligible~* Philadelphia (Ph) chromosome status determined by cytogenetics, fluorescence in situ hybridization (FISH), and/or RNA analysis~  * Patients determined to be Ph chromosome negative by cytogenetics, but positive for BCR-ABL by FISH or polymerase chain reaction are considered Ph chromosome positive~ * Patients with Ph chromosome-positive disease may be up to age 65~* No myelodysplasia or other antecedent hematologic disorder~* Patients age 50 and under must be HLA typed during induction therapy of study treatment OR provide a written explanation for not undergoing HLA typing~  * A and B typing required~ * C and DR typing done if feasible~* Allogeneic stem cell transplantation patients must meet the following criteria:~  * Appropriate HLA histocompatible donor available~    * Ph chromosome-negative patients must have HLA identical sibling~   * Ph chromosome-positive patients must have HLA identical, HLA-matched unrelated, or haploidentical related donor~* Postinduction therapy:~  * CSF negative for leukemia~ * No occult or overt leukemic meningitis~ * Documented complete remission~PATIENT CHARACTERISTICS:~Age:~* 15 to 65~Performance status:~* Induction therapy:~  * Not specified~* Postinduction therapy:~  * 0-1~Life expectancy:~* Not specified~Hematopoietic:~* See Disease Characteristics~Hepatic:~* Induction therapy:~  * Direct bilirubin ≤ 2.0 mg/dL~* Postinduction therapy:~  * Direct bilirubin \< 2.0 mg/dL~ * SGPT or SGOT \< 3 times normal~Renal:~* Induction therapy:~  * Creatinine \< 2 mg/dL~* Postinduction therapy:~  * Creatinine ≤ 2 mg/dL~ * Creatinine clearance ≥ 60 mL/min~Cardiovascular:~* Induction and postinduction therapy:~  * No significant cardiac disease requiring digoxin and/or diuretics~ * No major ventricular dysrhythmia requiring medication~ * No ischemic heart disease requiring medication~* Postinduction therapy:~  * Cardiac ejection fraction ≥ 50% for patients under consideration for transplantation~Pulmonary:~* Induction therapy:~  * Not specified~* Postinduction therapy:~  * FEV_1 ≥ 60% of predicted for patients under consideration for transplantation~ * DLCO ≥ 50% of predicted for patients under consideration for transplantation~Other:~* Induction and postinduction therapy:~  * HIV negative~ * No concurrent organ damage or other medical problem (e.g., psychiatric disorder or drug abuse) that would preclude study therapy~ * Not pregnant~* Postinduction therapy:~  * No persistent infection~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No concurrent umbilical cord allogeneic transplantation~Chemotherapy:~* Not specified~Endocrine therapy:~* Prior corticosteroids for ALL allowed~Radiotherapy:~* Not specified~Surgery:~* Not specified~Other:~* Induction and postinduction therapy:~  * No other prior therapy for ALL~* Postinduction therapy:~  * No concurrent antibiotics

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Transplant (Type: EXPERIMENTAL): Allogeneic (if donor) or Autologous (if no donor) bone marrow transplant
- Conventional Consolidation/Maintenance (Type: ACTIVE_COMPARATOR): Consolidation/Maintenance Therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).